Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesRituximab: mechanism of actionMonoclonal antibodies targeting CD38 in hematological malignancies and beyondLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisIn vivo monitoring of natural killer cell trafficking during tumor immunotherapyImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesUnderstanding of molecular mechanisms in natural killer cell therapyLow Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.Antigenic modulation and rituximab resistance.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesFCGR3A polymorphism story: a new piece of the puzzle.FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaTargeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaNatural killer cell mediated cytotoxic responses in the Tasmanian devilA new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugTGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cellsTumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Selection and characterization of cell binding and internalizing phage antibodies.Opportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseEngineered antibody Fc variants with enhanced effector function.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodiesExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximabFc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.Cancer immunotherapy comes of ageBuilding better monoclonal antibody-based therapeutics.Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
P2860
Q21131216-6904EEC0-7AA3-496E-B834-5E3E35FFDA57Q24607358-E2356561-0E77-4F9D-83F7-8495398A5E5AQ26766718-045DB9DB-B402-4485-A39F-151B8E9953FDQ26849243-B625EB6F-9545-430E-BEA8-E8755978F0F6Q26852081-AF82B0EC-A2DB-42DB-9EDE-10AB5CD4A878Q27011245-375D6885-C4F4-4072-9C65-325F1F388C88Q28069362-640B305E-CE1B-4B78-8769-D6B2DB7FCA75Q28086976-A531737A-5438-4F82-B4EE-F15AE166E502Q30398870-0E94DB24-12B4-48F7-8313-0BFE32B590FEQ30432874-B0803D39-C050-4A9F-928E-B64627A97F45Q30439017-0C530341-E227-4286-8BBD-A6C860E49282Q30498394-47240D65-724C-4BE8-90FA-63A4B5073141Q33347589-4E90D8CB-827C-4908-BA67-94F75FEB6D04Q33403638-050CE601-9176-4BBC-99B8-5A384267CEDCQ33410392-A68258A2-0E3D-410F-8753-6C63F8C9592DQ33599174-92EFAA45-ECB2-4BB6-B546-E2B2397F6456Q33944427-F5D18B80-121A-43F7-ABFA-3633777FBE4BQ34007430-1D137586-2FB7-4731-B6F6-E927B8FD9B89Q34034657-2B01F143-805C-4CD1-A605-F0BEF40C77AFQ34065271-AC41C675-CF0D-4758-96A7-9D74C4713229Q34076526-4E340C20-B9E5-4A33-8946-5D57FCD66DDEQ34194706-A1904557-B2E2-4A92-8132-436EF5E85723Q34223872-A671D51F-EE27-4DAB-AA8A-7EFCF99E18FDQ34280931-44C12C07-77C8-4221-B2C6-5967ECDB3E91Q34307792-AA36A6BD-78D5-41B6-8613-B5ECC26A7F2DQ34424958-A09BF07B-DF09-4F5F-A9B8-6CAB23E3F104Q34574834-1ED3973C-D310-44CE-92F8-736375DD17C6Q34598149-22ECCB01-FCEC-4F2F-8ABB-4D7BDD593AD6Q34869927-2B9C24EA-8CA9-4993-973B-B019ADE0B6D4Q34989602-C3A5E425-BBE0-4F94-99BD-5B57AB3FD5DBQ35031732-C1DCAADD-2C90-4ADF-BF80-4B0105E43D5DQ35037803-EAE49059-4420-410C-9AED-9428B3A44450Q35218515-272F6112-8312-43F0-9456-D1E0F8E60CA0Q35230227-EAA3D8A0-6F2D-409C-85A2-CA4EF907F73EQ35232342-FFD8DC3C-6D03-4015-B48C-78BE9EE4E64DQ35525404-591AC2F8-EC6A-4567-9293-C5D2D625B058Q35635268-9C991986-49AD-48E8-9227-52117E4321B1Q35666338-A1DF02C9-1ECC-4EC3-94F1-61E63C9D3141Q35817552-5A935BCC-6E12-4B55-B70C-711FD1BE270AQ36007647-F329B13D-2BC1-48BE-9EE8-51FB5237DA94
P2860
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@en
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@nl
type
label
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@en
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@nl
prefLabel
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@en
Rituximab-dependent cytotoxici ...... entration-effect relationship.
@nl
P2093
P1433
P1476
Rituximab-dependent cytotoxici ...... centration-effect relationship
@en
P2093
Gilles Thibault
Hervé Watier
Philippe Colombat
Pierre Bardos
Sophie Tartas
Sébastien Dall'Ozzo
P304
P356
10.1158/0008-5472.CAN-03-2862
P407
P577
2004-07-01T00:00:00Z